You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Inducible HMGB1 antagonist for viral-induced acute lung injury.

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NHLBI

    For more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.

    SBC: Zylo Therapeutics Inc.            Topic: NIAMS

    Project Summary/Abstract Approximately 500,000 people in the U.S. suffer from cutaneous lupus lesions (CLE), with a significant impact on quality of life.4 Yet, there is no cure, the treatment options are limited, and no new drug has been FDA- approved for over 50 years.84 As such, CLE represents a high unmet need for directed therapeutics. Skin lesions are caused by a complex autoimmune response ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting macrophage maladaptation for bacterial sepsis treatment

    SBC: AcePre, LLC            Topic: NIAID

    Summary. Sepsis results in massive loss of life and places a significant economic burden on society. There are no effective treatments available for human sepsis other than antibiotics and life support. It is increasingly clear that sepsis is a bi-phasic process comprised of 1) an early high-energy demanding hyperinflammation state that can cause inflammatory shock and 2) a low energy supply immun ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing natural compound emodin as a therapy for alcoholic cardiomyopathy

    SBC: AcePre, LLC            Topic: NIAAA

    Project Summary: Alcoholic Cardiomyopathy (ACM) is the most prevalent form of ethanol-induced heart damage. Alcohol dose-dependently induces ACM, characterized by progressive reduction in myocardial contractility and ventricular dilatation, culminating in heart failure. At the cellular level, chronic alcohol consumption results in cardiomyocyte death, cardiac inflammation, and cardiac fibrosis. Th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Targeted ColQ gene therapy for Congenital Myasthenic Syndromes

    SBC: Amplo Biotechnology, Inc.            Topic: 106

    PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. 3D microprinting-enabled microinjection needle arrays for enhanced therapeutics delivery into the brain

    SBC: SEETRUE TECHNOLOGY, LLC            Topic: 101

    PROJECT SUMMARY Microinjection technologies underlie many research and clinical applications that require gene and cell delivery, including studies and emerging treatments of neurological conditions (e.g., neurodegenerative diseases, traumatic brain injury, and cancer). Unfortunately, challenges associated with the microinjection tools by which the viral vectors and cells inherent in these applica ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Design and Engineering of Biodegradable 3D Nanoprinted Microcarriers for HIV Drug Delivery

    SBC: INFRATRAC INC            Topic: NIAID

    Precise, customizable drug delivery remains a long-term goal, for HIV in particular, as such technologies would allow therapies tailored to a patient’s biological makeup and potentially improve adherence. Extended-release methods address part of the issue, but face limitations. A novel drug delivery system could offer better pediatric dosing, via both oral and new routes of administration. Exist ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Jigsawdio: an AudioVisual Jigsaw Puzzle for People with Alzheimer's Disease and Alzheimer's-Disease-Related Dementias

    SBC: CALLAHAN-YOUNG LLC            Topic: NIA

    Social isolation leads to loneliness, which is linked to depression, stress, high blood pressure, and poor sleep, all of which accelerate cognitive decline. The prolonged social isolation that resulted from the COVID-19 pandemic has further highlighted the importance of social connection. Developing new strategies to support AD/ADRD patients and their families is a public health priority, particul ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma

    SBC: APIE THERAPEUTICS INC            Topic: NHLBI

    ABSTRACT The goal of this STTR proposal is to develop a novel anti-fibrotic agent suitable for oral administration which could be used to safely and effectively treat Systemic Sclerosis (SSc), or Systemic Scleroderma patients. SSc is one of the most disabling and lethal immune-mediated rheumatic disorders. SSc is a rare disease, affecting 40,000-150,000 people in the United States and conferring a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis

    SBC: GLYCOPATH INC            Topic: 400

    Lupus nephritis (LN), an immune complex-mediated glomerulonephritis, affects up to two-thirds of patients with systemic lupus erythematosus. Despite standard treatment protocols, progression of the most aggressive forms of LN (class III and IV) to end-stage renal failure remains high. Thus, there is a need for biomarkers of therapeutic response that would allow physicians to make better-informed t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government